Article
CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab.
Journal of translational medicine - 1 Apr 2015
Niehr Franziska, Weichert Wilko, Stenzinger Albrecht, Budach Volker, Tinhofer Ingeborg
Abstract excerpt
BACKGROUND: The mammalian target of rapamycin (mTOR) signaling pathway plays a pivotal role in numerous cellular processes involving growth, proliferation and survival. The purpose of this study was to investigate the anti-tumoral effect of the mTOR inhibitor (mTORi) CCI-779 in HNSCC cell lines a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.